Rukmini Sivaraman Sells 11,810 Shares of Nutanix, Inc. Stock
| PPCB Stock | USD 0.0002 0.0001 33.33% |
About 65% of Propanc Biopharma's investor base is looking to short. The analysis of overall sentiment of trading Propanc Biopharma pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Propanc Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Propanc Biopharma stock news signals to limit their universe of possible portfolio assets.
Propanc |
Nutanix, Inc. CFO Rukmini Sivaraman sold 11,810 shares of Nutanix stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of 66.63, for a total value of 786,900.30. Following the completion of the transaction, the chief financial officer now owns 190,882 shares in the
Read at thelincolnianonline.com
 |
Propanc Biopharma Fundamental Analysis
We analyze Propanc Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Propanc Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Propanc Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Propanc Biopharma is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Propanc Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Propanc Biopharma pink sheet to make a market-neutral strategy. Peer analysis of Propanc Biopharma could also be used in its relative valuation, which is a method of valuing Propanc Biopharma by comparing valuation metrics with similar companies.
Peers
Propanc Biopharma Related Equities
| HEPA | Hepion Pharmaceuticals | 9.30 | ||||
| CVAC | CureVac NV | 9.29 | ||||
| ENVB | Enveric Biosciences | 9.09 | ||||
| OCEA | Ocean Biomedical | 5.26 | ||||
| ZURA | Zura Bio | 2.00 | ||||
| VIR | Vir Biotechnology | 1.87 | ||||
| KRYS | Krystal Biotech | 1.96 | ||||
| ELEV | Elevation Oncology | 3.39 |
Complementary Tools for Propanc Pink Sheet analysis
When running Propanc Biopharma's price analysis, check to measure Propanc Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Propanc Biopharma is operating at the current time. Most of Propanc Biopharma's value examination focuses on studying past and present price action to predict the probability of Propanc Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Propanc Biopharma's price. Additionally, you may evaluate how the addition of Propanc Biopharma to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Correlations Find global opportunities by holding instruments from different markets |